Eupraxia Pharmaceuticals Inc. (TSX: EPRX)
Health Care · Biotechnology · CA
CA$9.35
-12.04% today · +13.3% 1Y
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $435.64M and employs 49 people.
Over the last twelve months the share price has gained 13.3%, trading between 7.35 and 13.08.
Tweenvest scores Eupraxia Pharmaceuticals Inc. across four factors: quality 35/100, value 71/100. Its strongest factor is value.
EPRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $435.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.00
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- CA$13.08
- 52-week low
- CA$7.35
- Avg volume (3M)
- —
- Shares outstanding
- 65.91M
- Employees
- 49
- Next earnings
- —
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
- ISIN
- CA29842P1053
- Founded
- 2011
- Listed since
- Mar 9, 2021
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kamada Ltd.TASE: KMDA | $453.92M | ₪24.32 | +2.83% |
| Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022 | $445.65M | CN¥5.76 | -7.10% |
| Guanhao Biotech Co.,Ltd.SZSE: 300238 | $442.97M | CN¥10.79 | -8.71% |
| REGENXBIO Inc.NasdaqGS: RGNX | $440.97M | $6.68 | -6.83% |
| Avacta Group PlcAIM: AVCT | $435.09M | £0.67 | +2.29% |
| Egetis Therapeutics AB (publ)OM: EGTX | $433.80M | Skr9.24 | -6.95% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $433.32M | $8.00 | -2.20% |
| Allogene Therapeutics, Inc.NasdaqGS: ALLO | $431.86M | $1.25 | -6.02% |
Figures last refreshed Oct 18, 2026.